These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24495103)

  • 1. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment.
    Theede K; Kiszka-Kanowitz M; Nielsen AM; Nordgaard-Lassen I
    Scand J Gastroenterol; 2014 Apr; 49(4):418-23. PubMed ID: 24495103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.
    Schoepfer AM; Beglinger C; Straumann A; Safroneeva E; Romero Y; Armstrong D; Schmidt C; Trummler M; Pittet V; Vavricka SR
    Inflamm Bowel Dis; 2013 Feb; 19(2):332-41. PubMed ID: 23328771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.
    Turner D; Leach ST; Mack D; Uusoue K; McLernon R; Hyams J; Leleiko N; Walters TD; Crandall W; Markowitz J; Otley AR; Griffiths AM; Day AS
    Gut; 2010 Sep; 59(9):1207-12. PubMed ID: 20801771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.
    Julsgaard M; Hvas CL; Gearry RB; Vestergaard T; Fallingborg J; Svenningsen L; Kjeldsen J; Sparrow MP; Wildt S; Kelsen J; Bell SJ
    Inflamm Bowel Dis; 2017 Jul; 23(7):1240-1246. PubMed ID: 28498159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis.
    Tursi A; Elisei W; Giorgetti G; Aiello F; Brandimarte G
    Minerva Gastroenterol Dietol; 2011 Sep; 57(3):247-55. PubMed ID: 21769075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial.
    Langhorst J; Boone J; Lauche R; Rueffer A; Dobos G
    J Crohns Colitis; 2016 Jul; 10(7):786-94. PubMed ID: 26874351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.
    Lobatón T; Rodríguez-Moranta F; Lopez A; Sánchez E; Rodríguez-Alonso L; Guardiola J
    Inflamm Bowel Dis; 2013 Apr; 19(5):1034-42. PubMed ID: 23470502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers.
    Berry N; Sinha SK; Bhattacharya A; Prasad KK; Vaishnavi C; Vaiphei K; Samanta J; Prasada R; Dhaka N; Kochhar R
    Dig Dis Sci; 2018 Jun; 63(6):1541-1550. PubMed ID: 29564671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis.
    Kawashima K; Ishihara S; Yuki T; Fukuba N; Oshima N; Kazumori H; Sonoyama H; Yamashita N; Tada Y; Kusunoki R; Oka A; Mishima Y; Moriyama I; Kinoshita Y
    BMC Gastroenterol; 2016 Apr; 16():47. PubMed ID: 27071448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Fecal Calprotectin Testing Predicts Mucosal Healing Better than C-reactive Protein and Serum Tumor Necrosis Factor α in Patients with Ulcerative Colitis.
    Voiosu T; Benguş A; Bălănescu P; Dinu R; Voiosu A; Băicuş C; Mateescu B
    Rom J Intern Med; 2015; 53(3):253-60. PubMed ID: 26710501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Renzulli P; Seibold F
    Inflamm Bowel Dis; 2009 Dec; 15(12):1851-8. PubMed ID: 19462421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers.
    Bennebroek Evertsz' F; Nieuwkerk PT; Stokkers PC; Ponsioen CY; Bockting CL; Sanderman R; Sprangers MA
    J Crohns Colitis; 2013 Dec; 7(11):890-900. PubMed ID: 23269224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.
    Guardiola J; Lobatón T; Rodríguez-Alonso L; Ruiz-Cerulla A; Arajol C; Loayza C; Sanjuan X; Sánchez E; Rodríguez-Moranta F
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1865-70. PubMed ID: 24993368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
    Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
    Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.